Clinical trials: Plaque-type Psoriasis
Plaque Type Psorisis, Non-pustular Palmoplantar Psoriasis
Clinical Study on the Medical Devices PROXERA PSOMED 20 and PROXERA PSOMED 40 for the Treatment of Plaque Psoriasis and Non-pustular Palmoplantar Psoriasis
This single-center interventional study was designed to evaluate the efficacy and safety of two CE-marked topical medical devices: PROXERA PSOMED 20 is being studied in participants with non-palmoplantar plaque psoriasis, while…
- Trial name
- PASI (NCT07545902)
- Testing
- PROXERA PSOMED 20 cream; PROXERA PSOMED 40 gel
- Where
- Italy
- Volunteers
- 35 people
- Sponsor
- ICIM International S.r.l.
Plaque Psoriasis
Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
The purpose of this study was to determine if secukinumab is effective and safe in the treatment of plaque type psoriasis
- Trial name
- NCT03066609
- Testing
- Secukinumab 150 mg s.c., Secukinumab 300 mg s.c.
- Where
- 32 sites in China, Hungary and 4 more
- Volunteers
- 543 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Plaque-type Psoriasis
A Dose Ranging Study of AIN457 in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
The purpose of the study is to determine whether, in patients with moderate to severe plaque-type psoriasis, AIN457 administered subcutaneously reduces the severity of psoriasis symptoms and the extent to which the patient's body…
- Trial name
- NCT01071252
- Testing
- AIN457
- Where
- 19 sites in United States, Canada and 4 more
- Volunteers
- 125 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis-Type Psoriasis, Plaque-Type Psoriasis
Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis
The study will test the safety and tolerability of Apremilast twice a day in participants with recalcitrant plaque type psoriasis.
- Trial name
- NCT00521339
- Testing
- Apremilast
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- Amgen
Psoriasis, Metabolic Syndrome
Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome
This study was a randomized, open-label, parallel-group, active comparator controlled study with two treatment arms designed to answer the question whether the combination of Secukinumab with lifestyle intervention could…
- Trial name
- METABOLYX (NCT03440736)
- Testing
- Secukinumab, Life-style intervention
- Where
- 75 sites in Germany
- Volunteers
- 781 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
An Open-Label, Multi-Center Trial in the Treatment of Subjects With Moderate to Severe Plaque Type Psoriasis
This is a study of a new oral drug used for the treatment of psoriasis. All subjects will get active medication, there is no placebo arm.
- Trial name
- NCT00725348
- Testing
- Talarozole
- Where
- 2 sites in Netherlands
- Volunteers
- 19 people
- Sponsor
- Stiefel, a GSK Company
Psoriasis
BIRB 796 BS Versus Placebo in Patients With Moderate to Severs Plaque-type Psoriasis
The clinical objective of this study was to determine the effect of BIRB 796 BS on pharmacodynamic markers of psoriasis as a measure of efficacy, to determine the population pharmacokinetics of BIRB 796 BS and to determine the…
- Trial name
- NCT02209753
- Testing
- BIRB 796 BS, low dose, BIRB 796 BS, medium dose 1, BIRB 796 BS, medium dose 2
- Volunteers
- 182 people
- Sponsor
- Boehringer Ingelheim
Plaque Psoriasis
A Study Comparing AIN457 to Placebo in Subjects With a Diagnosis of Moderate to Severe Stable Plaque Psoriasis
This is a two-arm, parallel group, double-blind, placebo-controlled proof-of-concept study comparing 3 mg/kg of AIN457 to placebo.
- Trial name
- NCT00669916
- Testing
- AIN457
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Follow-Up Study of Patients Previously Treated With Pimecrolimus Tablets for Chronic Plaque-Type Psoriasis
This extension study is being conducted to collect post-treatment safety information on patients who previously participated in the core clinical trial.
- Trial name
- NCT00098189
- Sponsor
- Novartis
Psoriasis
KX01 Ointment Phase 1 Study in Patients With Plaque Type Psoriasis
This is a Phase I dose escalation study to assess the safety, tolerability and activity of three different strengths of topical KX01 in the treatment of patients with plaque-type psoriasis.
- Trial name
- NCT05522816
- Testing
- KX01 0.01% (0.1 mg/g), KX01 0.1% (1.0 mg/g), KX01 1% (10 mg/g) for 5 days
- Volunteers
- 28 people
- Sponsor
- PharmaEssentia
Psoriasis
An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers
This is Part 1 of a two-part, randomized, double-blind, placebo-controlled study in which VTP-43742 was administered to participants; Part 1 in healthy volunteers and Part 2 in psoriatic participants.
- Trial name
- NCT03724292
- Testing
- VTP-43742
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Vitae Pharmaceuticals Inc., an Allergan affiliate
Chronic Plaque-type Psoriasis
Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis
A randomized, double-blind, placebo and positive controlled, single and multiple dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of CJM112 in chronic plaque-type psoriasis patients.
- Trial name
- NCT01828086
- Testing
- CJM112, Secukinumab
- Where
- 18 sites in United States
- Volunteers
- 95 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Plaque Type Psoriasis
The purpose of the study is to evaluate the effectiveness and safety of infliximab (Remicade) in patients with plaque-type psoriasis.
- Trial name
- NCT00230529
- Testing
- infliximab
- Volunteers
- 249 people
- Sponsor
- Centocor, Inc.
Psoriasis
Efficacy and Safety Study of Subcutaneous Secukinumab in Treatment of Subjects With Moderate to Severe Chronic Plaque-type Psoriasis as Compared to Etanercept and Placebo.
This withdrawn study was to assess the safety and efficacy of secukinumab compared to etanercept and placebo in patients who have moderate to severe, chronic, plaque-type psoriasis.
- Trial name
- NCT01900782
- Testing
- Intervention A, Intervention B
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Safety and Efficacy Study of A Novel Ointment to Treat Plaque Type Psoriasis
The purpose of this study is to evaluate the safety and efficacy of AN2728 Ointment, 5%, compared to Ointment Vehicle, applied twice daily for 12 weeks, in the treatment of plaque type psoriasis
- Trial name
- NCT00755196
- Testing
- AN2728, Ointment vehicle
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- Pfizer
Psoriasis
Double-Blind, Randomized, Placebo-controlled Comparison of CC-10004 in Subjects With Moderate to Severe Plaque Type Psoriasis
There is an unmet medical need for safe, effective oral therapy for moderate-to-severe psoriasis. CC-10004 will be evaluated in a controlled setting of a clinical study.
- Trial name
- PSOR-003 (NCT00606450)
- Testing
- CC-10004
- Where
- 31 sites in Canada, Czechia and 1 more
- Volunteers
- 260 people
- Sponsor
- Amgen
Plaque Psoriasis
TSO for Plaque Psoriasis
This is a randomized, blinded, multicenter study to assess the safety and treatment effect of 12 weeks of Trichuris suis ova in subjects diagnosed with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT02011269
- Testing
- Trichuris Suis Ova
- Sponsor
- Coronado Biosciences, Inc.
Chronic Plaque Psoriasis
Paired-Comparison Study Evaluating the Efficacy and Safety of E6201 Versus Vehicle for the Treatment of Plaque-Type Psoriasis
This is a double-blind, multicenter study to assess the efficacy and safety of E6201 topical administration to pre-identified marker lesions in adult subjects with chronic plaque type psoriasis.
- Trial name
- NCT00539929
- Testing
- E6201 0.005%, E6201 0.01%, E6201 0.03%
- Where
- 12 sites in United States
- Volunteers
- 100 people
- Sponsor
- Eisai Inc.
Psoriatic Plaque
Laser-assisted Topical Administration of Etanercept (Enbrel®) in Patients With Mild to Moderate Plaque-type Psoriasis
The purpose of this study is to assess the feasibility and safety of topical administration of etanercept via AFL micropores to psoriatic plaques in patients with mild to moderate plaque-type psoriasis.
- Trial name
- NCT02999776
- Testing
- Laser microporation alone, Standard of care-daily administration of Daivobet, Laser microporation + topical application of Etanercept
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- Pantec Biosolutions AG
Psoriasis, Psoriatic Arthritis
Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type Psoriasis
This study will test the clinical effectiveness and safety of two orally administered doses of apremilast compared to placebo in Japanese patients with moderate-to-severe plaque-type psoriasis.
- Conditions
- Psoriasis, Psoriatic Arthritis, Psoriasis Arthropatica
- Trial name
- NCT01988103
- Testing
- Apremilast
- Where
- 56 sites in Japan
- Volunteers
- 254 people
- Sponsor
- Amgen